ChatGPTを活用して業務のAI化を進めています。プロンプトエンジニアリングの専門家です！と、名乗れるレベルではありませんが、かなり色々使いこなしてきています。この１年、病気で失われた能力は、別な能力を発達させる、進化することで生き残っていこうと思います。
<><><>
23/10/07
[HTML] Integrated bioinformatics analysis for the identification of idiopathic pulmonary fibrosis–related genes and potential therapeutic drugs
Z Zhang, Q Guan, Y Tian, X Shao, P Zhao, L Huang… - BMC Pulmonary Medicine, 2023
… The pathogenesis of idiopathic pulmonaryfibrosis (IPF) remains unclear. We sought to identify IPF-related genes that may participate in the … for the mechanisms of disease development in IPF at the transcriptome level and explore …
- 特発性肺線維症関連遺伝子と潜在的な治療薬を同定するための統合バイオインフォマティクス分析
[HTML] Circulating inflammatory cytokines and risk of idiopathic pulmonary fibrosis: a Mendelian randomization study
Q Jia, Y Lei, S Chen, S Liu, T Wang, Y Cheng - BMC Pulmonary Medicine, 2023
… to idiopathic pulmonary fibrosis (IPF). However, it was still unclear whether there were casual associations between circulating inflammatory cytokines and IPF … cytokines were associated with IPF development using a two-sample Mendelian …
- 循環炎症性サイトカインと特発性肺線維症のリスク: メンデルランダム化研究
The molecular mechanisms of extracellular matrix-derived hydrogel therapy in idiopathic pulmonary fibrosis models
D Evangelista-Leite, ACO Carreira, MY Nishiyama… - Biomaterials, 2023
… Idiopathic Pulmonary Fibrosis (IPF) is a progressively debilitating lung condition … to prevent fibrosis in bleomycin-induced IPFmodels, and unravel their underlying molecular … in rat models of bleomycin-induced pulmonary fibrosis. ECM-derived …
- 特発性肺線維症モデルにおける細胞外マトリックス由来ハイドロゲル療法の分子機構
COMBINATION THERAPY WITH PIRFENIDONE AND NINTEDANIB IN IDIOPATHIC PULMONARY FIBROSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS
T GANDHI, A SHAH, P SALUJA, E KOCUREK - CHEST, 2023
PURPOSE: Idiopathic pulmonary fibrosis(IPF) is a chronic, progressive, fibrotic interstitial lung disease. Nintedanib and pirfenidone are anti-fibrotic medications that have been shown to slow the decline in forced vital capacity (FVC) in IPF. However …
- 特発性肺線維症におけるピルフェニドンとニンテダニブの併用療法：系統的レビューとメタ分析
Genetic and Lifestyle Risk Factors for Idiopathic Pulmonary Fibrosis: Greater Than the Sum of Its Parts
CA Newton - CHEST, 2023
… idiopathic pulmonary fibrosis (IPF). A multitude of genes and variants have been discovered that implicate a host of biologic processes that contribute to IPF … However, only a portion of IPF cases harbor an implicated genetic variant, which …
- 特発性肺線維症の遺伝的およびライフスタイルの危険因子: 部分の合計より大きい
SWITCHING ANTIFIBROTIC MEDICATION IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF): A DESCRIPTIVE STUDY
Y SUN, J GIRARD, KG DSOUZA, T LUCKHARDT… - CHEST, 2023
… CONCLUSIONS: Among IPF patients who do not tolerate first-line AFT, switching antifibrotics may be a feasible treatment strategy and can … and might improve quality of life among IPFpatients. This study supports the concept that IPF patients …
- 特発性肺線維症（IPF）患者における抗線維化薬の切り替え：記述的研究
EXTRACELLULAR VESICLE-ENCAPSULATED MICRO-RNAS IN IDIOPATHIC PULMONARY FIBROSIS: A PILOT STUDY
C ECKHARDT, S BENESH, C DEPENDER… - CHEST, 2023
… drivers of idiopathic pulmonary fibrosis(IPF). However, no prior studies have characterized the role of total plasma EV-miRNAs … IPF. We aimed to evaluate associations of plasma EV-miRNAs with IPFpathology and markers of IPF severity …
ANTIFIBROTIC TREATMENT AND CLINICAL OUTCOMES IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF): A PROSPECTIVE LONG-TERM FOLLOW …
Y LEI, ALI AKMAL, J VILKAS, TN LIESCHING - CHEST, 2023
… pirfenidone, among IPF patients and evaluate the effects on IPF exacerbation and mortality … We enrolled patients with IPF who came to our hospital for pulmonologist visit from June 1, … were reviewed to determine if the event was an …
- 特発性肺線維症（IPF）患者における抗線維症治療と臨床転帰：前向き長期追跡研究
THE IMPACT OF THE PRESENCE OF EMPHYSEMA ON THE CLINICAL COURSE OF PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
H KANG, JINHWA SONG, Y PARK, HAK WON… - CHEST, 2023
… PURPOSE: Emphysema is often observed in patients with idiopathic pulmonary fibrosis(IPF). However, it is unclear whether the clinical … course in patients with IPF. METHODS: Data were collected retrospectively from patients diagnosed with IPF …
- 特発性肺線維症患者の臨床経過に対する肺気腫の存在の影響
TRAJECTORIES OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
AMYL OLSON, J TODD, LD SNYDER, P LI, ML NEELY - CHEST, 2023
… PURPOSE: Idiopathic pulmonary fibrosis(IPF) is associated with impairment in health-related quality of life (HRQL). We evaluated trajectories of HRQL in patients with IPF in the prospective observational IPF-PRO Registry. METHODS: Patients …
- 特発性肺線維症患者における健康関連の生活の質の軌跡
23/10/05
[HTML] Identifying potential biomarkers of idiopathic pulmonary fibrosis through machine learning analysis
Z Wu, H Chen, S Ke, L Mo, M Qiu, G Zhu, W Zhu, L Liu - Scientific Reports, 2023
… Idiopathic pulmonary fibrosis (IPF) is the most common and serious type of idiopathic … Until recently, patients with idiopathicpulmonary fibrosis have a poor prognosis, high mortality, … Therefore, we aimed to identify biomarkers for …
Myeloid Heterogeneity Mediates Acute Exacerbations of Pulmonary Fibrosis
JL Larson-Casey, K Saleem, R Surolia, J Pandey… - The Journal of Immunology, 2023
… is linked to the development of idiopathicpulmonary fibrosis (IPF) and increases the incidence of acute exacerbations of IPF. In addition to … lm [PM2.5]) is a risk factor for increased mortality in subjects with IPF. In this article, we show that …
- 骨髄の不均一性が肺線維症の急性増悪を媒介する
[PDF] Transbronchial cryobiopsy and Neutrophil Lymphocyte Ratio-new precision medicine tools and markers in Interstitial Lung Disease
TA Mikolasch - 2023
… form Idiopathic Pulmonary Fibrosis (IPF), often have a devastating impact on afflicted patients with the median survival at diagnosis of IPF … Available treatment in the form of antifibrotics for IPF and often immunosuppression for other fILD comes …
- 経気管支凍結生検と好中球リンパ球比 - 間質性肺疾患における新しい精密医療ツールとマーカー
PHARMACOKINECTS STUDY TO EVALUATE DRUG-DRUG INTERACTIONS (DDI) BETWEEN HZN-825 AND PIRFENIDONE/NINTEDANIB
Y SONG, K HUDSON, Z YE, WEI CHEN, L HAWLEY… - CHEST, 2023
… a potential treatment for progressive fibrotic diseases in ongoing Phase 2 trials for both dcSSc and idiopathic pulmonary fibrosis(IPF). Pirfenidone and nintedanib are standard of care therapy for IPF treatments. Nintedanib was also approved for SSc-ILD …
- HZN-825 とピルフェニドン/ニンテダニブ間の薬物間相互作用 (DDI) を評価するための薬物動態研究
Serum C-reactive protein is associated with earlier mortality across different interstitial lung diseases.
CJW Stock, WG Bray, V Kouranos, J Jacob, M Kokosi… - Respirology (Carlton, Vic.), 2023
… Patients included in the study were: idiopathic pulmonary fibrosis (IPF) n = 422, fibrotic hypersensitivity pneumonitis (fHP) n = 233, rheumatoid arthritis associated ILD (RA-ILD) n = 111 and Systemic Sclerosis associated ILD (SSc-ILD) n = 86 …
- 血清 C 反応性タンパク質は、さまざまな間質性肺炎の早期死亡率と関連しています。
Mollicutes-related infections in thoracic surgery including lung and heart transplantation: a systematic review.
E Farfour, M Vasse, A Vallée - The Journal of Heart and Lung Transplantation, 2023
… Eleven patients were lung-transplanted for pulmonary fibrosis, one for chronic obstructive pulmonary disease (COPD), one for pulmonary sarcoidosis, and two for emphysema. All patients had neurologic disorder manifestations as their first …
- 肺移植および心臓移植を含む胸部手術におけるモリクテス関連感染症：系統的レビュー。
23/10/03
Catch your breath: The protective role of the angiotensin AT2 receptor for the treatment of idiopathic pulmonary fibrosis
ON Young, JE Bourke, RE Widdop - Biochemical Pharmacology, 2023
… Progressive scarring of the lung, or pulmonary fibrosis, can occur in a number of conditions where there is chronic injury and inflammation in the lung. While this review focuses on idiopathic pulmonary fibrosis(IPF), other respiratory diseases …
- 息を止めましょう：特発性肺線維症の治療におけるアンジオテンシン AT2 受容体の保護的役割
[HTML] KIF15 missense variant is associated with the early onset of idiopathic pulmonary fibrosis
M Hollmén, A Laaka, JJ Partanen, J Koskela, E Sutinen… - Respiratory Research, 2023
… Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease that is accompanied by respiratory symptoms, primarily dyspnoea, and a … Studies are slowly unravelling the aetiology of IPF with evidence of genetic susceptibility …
- KIF15ミスセンス変異体は特発性肺線維症の早期発症と関連している
[PDF] Role of lung ornithine aminotransferase in Idiopathic Pulmonary Fibrosis: regulation of mitochondrial ROS generation and TGF-β1 activity
SW Park, JU Lee, S Kisung, J Hong, H Shin, E Park… - 2023
… IPF patients from other IPF cohort 15,16. Next, we measured BALF OAT levels in IPF and control subjects and found signi cantly increased OAT levels in the IPF … As was same of microarray data from other IPF cohort 16, our data also suggest that …
- 特発性肺線維症における肺オルニチンアミノトランスフェラーゼの役割：ミトコンドリアROS生成とTGF-β1活性の調節
Endothelial to mesenchymal transition: a novel pathological feature of pulmonary fibrosis
SS Sohal - European Respiratory Journal, 2023
… endothelial cell-like myofibroblasts and their role in pulmonary fibrosis using mouse models. I highly commend this work … pulmonaryfibrosis, I wish to bring forth some novel insights from our recent work published in ERJ Open Research [2, 3] …
- 内皮から間葉への移行：肺線維症の新たな病理学的特徴
[HTML] Regulation of epithelial transitional states in murine and human pulmonary fibrosis
F Wang, C Ting, KA Riemondy, MT Douglas, KM Foster… - The Journal of Clinical …, 2023
… Idiopathic Pulmonary Fibrosis (IPF) is a progressive scarring disease arising from impaired … In IPF, transitional AECs accumulate with ineffectual AEC1 differentiation. However, whether … and fibrosis resolve in mouse models but accumulate in IPF …
- マウスおよびヒトの肺線維症における上皮の移行状態の制御
[HTML] Lung immune signatures define two groups of end-stage IPF patients
T Cruz, N Mendoza, S Casas-Recasens, G Noell… - Respiratory Research, 2023
… The role of the immune system in the pathobiology of Idiopathic Pulmonary Fibrosis(IPF) is controversial. … Idiopathic PulmonaryFibrosis (IPF) is an interstitial lung disease of unknown origin characterized by progressive lung fibrosis [1]. The …
- 肺の免疫サインにより末期 IPF 患者の 2 つのグループが定義される
[PDF] Serum heme oxygenase-1 as a prognostic biomarker in patients with acute exacerbation of interstitial lung disease
Y Tagami, Y Hara, K Murohashi, R Nagasawa, H Fujii… - 2023
… of idiopathic pulmonary brosis (IPF), the in-hospital mortality rate is reported to be in more than 50%.A retrospective cohort study for AE patients with non-IPF and IPF … HO-1 was signi cantly higher in AE of IPF compared with that in AE of IIPs other than …
- 間質性肺疾患の急性増悪患者における予後バイオマーカーとしての血清ヘムオキシゲナーゼ-1
Metabolomics and Transcriptomic Approach to Understand the Pathophysiology of Interstitial Lung Disease
S Dasgupta, A Bhattacharya, P Choudhury, N Ghosh… - … Applications in Genetic …, 2023
… ILD registries comprising patients from Western countries suggest that idiopathicpulmonary fibrosis (IPF) and sarcoidosis are the most common phenotypes. However, the ILD registry of India indicates HP to be the most common, which accounts for …
- 間質性肺疾患の病態生理学を理解するためのメタボロミクスとトランスクリプトームのアプローチ
[PDF] A First‐In‐Human Phase 1 Study of SHR‐1906, a Humanized Monoclonal Antibody Against Connective Tissue Growth Factor, in Healthy Participants
LL Song, HY Zhou, PP Ye, Q Li, KG Chen, YH Zhang… - Clinical and Translational …, 2023
… New therapeutic targets and drugs are urgently needed to halt the fibrosing process in idiopathic pulmonary fibrosis (IPF). SHR-1906 is a novel fully humanized monoclonal antibody against the connective tissue growth factor (CTGF) which plays …
- 結合組織増殖因子に対するヒト化モノクローナル抗体であるSHR-1906の健常参加者を対象としたファーストインヒト第1相試験
<><><>
特発性肺線維症( idiopathic pulmonary fibrosis (IPF) )関連の学術的情報収集してシェアしています。Google Scholar SearchのUpdateを定期的に掲載しています。GoogleのAIが一定の重み付けはしているとは思いますが、玉石混交です。
当面、毎週アラートの内容をアップしていこうと思います。
###
